LY3526318
Phase 2Small molecule
Eli LillyLY3526318 is one of 45 small molecule programs targeting Osteoarthritis, Knee. It is currently in Phase 2.
1
Indications
8
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
47 competitors in Osteoarthritis, Knee
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Voltaren
NovartisApproved
Cymbalta
Jazz PharmaceuticalsApproved
Marinol
Jazz PharmaceuticalsApproved
Medrol
PfizerApproved
Colcrys
Jazz PharmaceuticalsApproved
Calciferol
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Plaquenil
Jazz PharmaceuticalsApproved
Cyklokapron
JJ Molner
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
ART2 trials
Osteoarthritis1 trial
Neuropathic Pain1 trial
2 more indications
Osteoarthritis, Knee1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3526318. EMBL-EBI & Wellcome Sanger Institute.
- [4]